Why carry out this study?

Data on the real-world effectiveness and tolerability of apremilast for treatment of plaque psoriasis are limited.

This prospective observational study assessed the effectiveness and safety of apremilast for the treatment of moderate to severe psoriasis in Belgian clinical practice, from the perspectives of the patient and the physician.

What was learned from the study?

Using the Patient Benefit Index for Skin Diseases, patients identified treatment goals relating to physical impairment as most important and the majority of patients achieved these treatment goals following 6 months of apremilast treatment.

Apremilast improved patient-reported outcomes, including quality of life, psoriasis severity and treatment satisfaction, and was well tolerated with no new safety signals identified.

Our real-world data indicate that apremilast fulfils the expectations of Belgian patients with moderate to severe psoriasis, and from the perspectives of both the patient and physician, has a positive impact on their disease.